U.S. Department of Defense Turns to Pluristem for Preemptive Radiation Antidote as North Korea Threats Escalate
The United States Department of Defense (DOD) will fund a study of Pluristem's cell therapy PLX-R18 evaluating its use as an antidote for Acute Radiation Syndrome (ARS) when administered prior to, or within 24 hours of, exposure to deadly radiation. Studies will be led by the DOD's Armed Forces Radiobiology Research Institute (AFRRI) whose mission is to protect the U.S. military from ionizing radiation.
View full press release